Health Canada has for the first time approved a disease-modifying drug for Alzheimer’s, offering new hope for patients seeking to slow the progression of the disease. The antibody drug, lecanemab, doesn’t stop the relentless march of the disease, but rather slows its progression for some people with mild cognitive impairment or early-stage dementia. But as health reporter Kelly Grant reports, approval does not guarantee that the complex and expensive intravenous therapy will be widely available in Canada. Read more.

Also this week: It’s nearly time to change the clocks. Here’s what it means for your sleep and your overall health.

From food and drink to parenting and relationships, The Globe and Mail publishes several newsletters designed to keep you healthy, active, and informed. Visit our signup page to subscribe.